Axsome Therapeutics Inc., of New York, said it raised approximately $23.3 million through the sale of 2.88 million shares under its existing at-the-market (ATM) facility with Leerink Partners LLC. The company intends to use the proceeds to continue to fund the ongoing clinical development of its late-stage product candidates and for other general corporate purposes.